1. Comparative Studies on the Efficacy and Safety of Ainuovirine-Based Versus Efavirenz-Based Antiretroviral Therapy in the Management of Persons Living with HIV: A Real-World Study in Guizhou, China.
- Author
-
Guo L, Fu Y, Xie X, Yan W, and Long H
- Subjects
- Humans, Male, Female, China, Adult, Retrospective Studies, Middle Aged, CD4 Lymphocyte Count, Viral Load drug effects, Treatment Outcome, HIV-1 drug effects, Reverse Transcriptase Inhibitors therapeutic use, Reverse Transcriptase Inhibitors adverse effects, RNA, Viral blood, Antiretroviral Therapy, Highly Active adverse effects, Antiretroviral Therapy, Highly Active methods, HIV Infections drug therapy, Benzoxazines therapeutic use, Benzoxazines adverse effects, Cyclopropanes therapeutic use, Alkynes therapeutic use, Anti-HIV Agents therapeutic use, Anti-HIV Agents adverse effects
- Abstract
In China, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are integral to the antiretroviral therapy (ART) regimen for persons living with HIV (PWH), comprising over 80% of such treatments. To broaden treatment options and improve therapeutic effectiveness, Ainuovirine (ANV), a new NNRTI, was authorized for ART in 2021. Nevertheless, the clinical efficacy of ANV and its impact on blood biochemical markers remain somewhat underexplored. This study seeks to evaluate ANV's clinical performance in ART and its influence on relevant treatment parameters. A retrospective analysis was performed on 208 patients treated with an ANV-based regimen from July 2021 to July 2023, monitoring indicator changes from baseline to week 24. The primary endpoint was the proportion of participants achieving HIV-1 RNA levels of less than 50 copies/mL by week 24. Secondary endpoints involved assessing variations in CD4
+ T cell counts and blood biochemical markers from baseline. These outcomes were also compared with data from 241 patients treated with an Efavirenz (EFV)-based regimen in the same time frame. The findings suggest that the ANV-based regimen is as effective as the EFV-based regimen in viral suppression ( p > .05) and offers superior improvements in lipid profiles, liver function, and immune system indicators, alongside fewer adverse reactions. These results affirm ANV's efficacy and safety as an antiretroviral therapy option, offering Acquired Immune Deficiency Syndrome patients a wider array of treatment possibilities and the potential for better treatment outcomes.- Published
- 2024
- Full Text
- View/download PDF